Ravi Kiron, Ph.D., MBA
Managing Director, BioPharm Strategy
Dr. Ravi Kiron is an experienced pharma/biotech/venture executive with decades of experience in discovery R&D, early to late stage clinical dev, IP, technology, BD, M&A, strategy, product commercialization, negotiating/executing key partnerships between academia, pharma & biotech, leveraging his extensive global networks in Cardiovascular, Oncology, Neuroscience, Wound Healing, AI, Microbiome, Drug Delivery, Diagnostics.
He was faculty, Cornell Univ Med College, University of Rhode Island, with operational, executive management roles at pharma: Pfizer – Cardiovascular R&D (Hypertension, CHF, Ischemia), Oncology clin dev (TarcevaÒ NSCLC), Strategic BD, M&A (WLA, PHA, biotech acquisitions); J&J/ALZA – Drug Delivery Innovation/Licensing; Merck KGaA/EMD Serono Silicon Valley Innovation Hub/Strategic Innovation investing in game changing technologies (AI, Microbiome, Organoids, Fertility, Electroceuticals, Longevity/Aging).
Dr. Kiron’s biotech tenure spans BD, IPO, pharma/university collaborations, fund raising (Aduro, KineMed, Amarantus, Arrien), consulting several dozen global biotech, pharma companies; cofounded 4 startups (C2N Dx, Navya, PKBio, iRetainRx); Corporate & Private Venture teams – SRI Ventures, Shang Pharma Innovation, Celtic Pharma, with biotech Board Advisory (Cytovia, Spanios, DataJoint, ARIZBio), University/Industry non-profit boards (UCSD, UCD, NCI, Pantheon, BIO, BTS).
Dr. Kiron earned BS Chemistry, MS Microbiology from University of Mumbai, India; PhD Biochemistry from Indian Institute of Science, India; MBA from Rensselaer Polytechnic Institute, New York, USA.